Application No. 10/686,517 Docket No.: 33396-198024

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A sprayable composition for topical application, comprising:

from about 0.0001% to about 30% of at least one medicament for systemic or topical availability,

at least one film former comprising from about 0.0001% to about 10% of the composition in at least one non-aqueous vehicle;

and at least one component selected from the group

at least one permeation enhancer;

at least one solubilizer; and

at least one plasticizer; and

at least one water soluble additive

the composition forming a stable, breathable film upon application to a surface.

- 2. (Original) The composition according to claim 1, comprising from about 0.0001% to about 10% of the at least one medicament.
- (Original) The composition according to claim 1, comprising from about 0.0001% to about 5% of the at least one medicament.
 - (Canceled).
 - 5. (Canceled).
- (Previously Presented) The composition according to claim 1, comprising at least one
 permeation enhancer in an amount of from about 0.0001% to about 8% of the composition.

Docket No.: 33396-198024

7. (Canceled)

 (Previously Presented) The composition according to claim 1, comprising at least one solubilizer in an amount of from about 0.0001% to about 10% of the composition.

9. (Canceled)

 (Previously Presented) The composition according to claim 1, comprising at least one plasticizer in an amount of from about 0.0001% to about 10% of the composition.

11. (Canceled)

 (Original) The composition according to claim 1, wherein the at least one medicament is locally or transdermally available.

13. (Canceled)

- 14. (Original) The composition according to claim 1, wherein the composition comprises at least one medicament which is released from the composition immediately upon application to a biological surface.
- 15. (Original) The composition according to claim 1, wherein the composition comprises at least one medicament which is released from the composition over an extended period of time after application to a biological surface.

16. (Canceled)

17. (Original) The composition according to claim 1, wherein the at least one medicament is selected from the group consisting of anti-emetics, anti-anginals, anti-inflammatory agents, steroids, steroid hormones, bronchodilators, drugs used to treat osteoporosis, drugs used to treat incontinence, antidepressants/anxiolytics, antimigraine agents, agents used in smoking cessation therapy, antidiarrheals, antiulcerants, anticholinerginics, anticonvulsants, drugs for mood disorders/obsessive compulsive disorder. ACE inhibitors, calcium channel blockers,

Application No. 10/686,517 Docket No.: 33396-198024

antihypertensives/diuretics, antiobesity drugs, hormonal peptides and analogues, drugs for benign prostatic hyperplasia/urinary retention and erectile dysfunctions, antiparkinson agents such as dopamine agonists and MAO inhibitors, drugs for sleep disorders and antidiabetic agents.

- 18. (Original) The composition according to claim 1, wherein the at least one medicament is selected from the group consisting of scopolamine, nitroglycerine, clonidine isosorbide dinitrate, propanolol hydrochloride, timolol maleate, clonazepam, verapamil, diclofenac sodium, naproxen sodium, ibuprofen, ketoprofen, indomethacin, piroxicam, ketorolac, tromethamine, nimesulide, hydrocortisone and esters thereof, dexamethasone, fluocinolone acetonide and betamethasone and salts thereof, estradiol and norethisterone or their pharmaceutically acceptable salts and combinations thereof, testosterone, progesterone, salbutamol and salts thereof, bambuterol, salmeterol xinafoate, fluticasone propionate, mometasone furoate, budesonide, beclomethasone dipropionate, sodium cromoglycate or isoprenaline sulphate, alendronic acid, pamidronic acid, etidronic acid or salts thereof, vasopressin, oxybutynin, imipramine, mitrazapine, desipramine, naratriptan, zolmitriptan, sumatriptan, nicotine, loperamide, misoprostol, hyoscyamine, atropine, trihexyphenidyl, lorazepam, diazepam, tiagabine, fluoxetine, paroxetine, lisinopril, trandolapril, amlodipine, felodipine, prazosin, amiloride, methamphetamine, sibutramine captopril. hydrochloride, nafarelin, leuprolide acetate, insulin, growth hormone and analogues thereof, doxazosin, tamsulosin, terazosin, finasteride, alprostadil, sildenafil citrate, bromocriptine, cabergoline, selegiline, melatonin, glimepiride, rosiglitazone, glyburide, glipizide and combinations thereof.
- 19. (Original) The composition according to claim 1, wherein the at least one medicament is present as a single enantiomer.
- 20. (Previously Presented) The composition according to claim 6, wherein the at least one permeation enhancer is selected from the group consisting of lipophilic solvents, surfactants, oleic acid, octyl dimethyl benzoic acid, menthol, mixed esters of capric and caprylic acid, polyhydric alcohols, dimethyl sulfoxide, dimethyl formamide, isopropyl myristate, Tween, sodium lauryl sulfate, propylene glycol, transcutol and combinations thereof.

Docket No : 33396-198024

- 21. (Canceled)
- 22. (Canceled)
- 23. (Currently Amended) The composition according to claim 1 [[22]]wherein the at least one non-aqueous vehicle solvent is selected from the group consisting of acetone, isopropyl alcohol, methylene chloride, methyl ethyl ketone, absolute alcohol, ethyl acetate, trichloromonofluoroethane (P11) and methylene dimethyl ether.
 - 24. (Canceled).
- 25. (Currently Amended) The composition according to claim 1 [[22]], <u>further comprising at least one propellant</u>, wherein the at least one propellant comprises from about 10% to about 90% of the composition.
- 26. (Currently Amended) The composition according to claim 25 [[22]], wherein the at least one propellant is selected from the group consisting of a hydrocarbon, a hydrofluorocarbon, hydrochlorofluorocarbon, a compressed gas propane, butane, isobutane, dimethylether, dichlorodifluoromethane (P12), trichloromonofluoromethane (P11), dichlorofluoroethane, monochlorodifluoromethane (P22), dichlorotetrafluoroethane (P134A), heptafluoropropane (P227B), nitrogen and carbon dioxide.
 - 27-30. (Canceled)
- 31. (Original) The composition according to claim 1, wherein the at least one film-former is selected from the group consisting of acrylic polymers or copolymers, polyvinyl acetate, cellulose acetate, polyvinyl alcohol, povidone, copolypovidone povidone vinyl acetate, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose and ethyl cellulose.
- 32. (Original) The composition according to claim 31, wherein the acrylic polymer or copolymer is selected from the group consisting of non-ionic copolymers of methyl methacrylate and butyl methacrylate, copolymers of dimethylamine ethyl methacrylate and a neutral methacrylic

acid ester, ammonio methacrylate copolymer type B, ammonio methacrylate copolymer type A, methacrylic acid copolymer type A and methacrylic acid copolymer type B.

- 33. (Previously Presented) The composition according claim 8, wherein the at least one solubilizer is selected from the group consisting of copolymers of dimethylamine ethyl methacrylate and a neutral methacrylic acid ester, a surfactant, a polyhydric alcohol, vitamin E, vitamin E TPGS (tocopheryl polyethylene 1000 succinate), labrasol, propylene carbonate, sodium lauryl sulphate, Tweens, spans, propylene glycol polyethylene glycol and combinations thereof.
 - 34. (Canceled).
- 35. (Previously Presented) The composition according to claim 10, wherein the at least one plasticizer is selected from the group consisting of triethyl citrate, dimethyl isosorbide, acetyltributyl citrate, castor oil, propylene glycol, polyethylene glycol, and combinations thereof.
 - 36. (Canceled)
 - 37. (Previously Presented) A composition comprising:

from about 0.0001% to about 30% of at least one medicament for topical or systemic availability,

at least one film-former comprising from about 0.0001% to about 10% of the composition,

at least one solubilizer,

at least one permeation enhancer, and

at least one vehicle:

said composition forming a stable, breathable film upon application to a surface

Docket No : 33396-198024

38. (Original) The composition according to claim 37, wherein the at least one medicament comprises from about 0.0001% to about 10% of the composition.

- 39. (Original) The composition according to claim 37, wherein the at least one medicament comprises from about 0.0001% to about 5% of the composition.
- 40. (Currently Amended) The composition according to claim 37, wherein the at least one film former comprises from about 0.0001% to about 10% of the composition, the at least one solubilizer comprises from about 0.0001% to about 10% of the composition, and the at least one permeation enhancer comprises from about 0.0001% to about 8% of the composition, and the at least one plasticizer comprises from about 0.0001% to about 10% of the compositio.

Claims 41-43 (Canceled).

- 44. (Original) The composition according to claim 37, further comprising from about 0.0001% to about 7% of at least one water soluble additive.
- 45. (Original) The composition according to claim 37, wherein the film-former is a non-ionic copolymer of methyl methacrylate and butyl methacrylate and the solubilizer is a copolymer of dimethylamine ethyl methacrylate and a neutral methacrylic acid ester.

Claims 46-73 (Canceled).

- 74. (Previously Presented) The sprayable composition of claim 1, further comprising dimethyl isosorbide.
- 75. (Previously Presented) The sprayable composition of claim 10, wherein the plasticizer is dimethyl isosorbide.
- 76. (New) The sprayable composition of claim 1, wherein the composition is not an aerosol.

Application No. 10/686,517 Docket No.: 33396-198024

 (New) The sprayable composition of claim 37, wherein the composition is not an aerosol.

- 78. (New) The sprayable composition of claim 1, comprising at least one film former comprising from about 0.0001% to 10% of the composition.
- 79. (New) The sprayable composition of claim 37, comprising at least one film former comprising from about 0.0001% to 10% of the composition.
- 80. (New) The composition according to claim 37, wherein the at least one vehicle comprises water, at least one non-aqueous solvent, or at least one propellant.
- 81. (New) The composition according to claim 37, wherein the at least one vehicle comprises from about 1% to about 20% (w/w) of at least one humectant.
- 82. (New) The composition according to claim 81, wherein the at least one humectant is selected from the group consisting of polyhydric alcohols polyvinyl pyrrolidone, propylene glycol, butylene glycol, a polyethylene glycol, glycerol and sorbitol.
- 83. (New) The composition according to claim 44, wherein the at least one water soluble additive is selected from the group consisting of propylene glycol, sodium lauryl sulfate, one or more polaxomers, polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, cetomacrogol, polyethylene glycol, diethylene glycol, monoethyl ether EP (transcutol), and combinations thereof.